Does Moderna Need to Start Making Money?

Published June 9, 2026 · Category: Finance

Overview

Moderna (NASDAQ: MRNA) is best known for its COVID-19 vaccines, which were fast-tracked for approval in 2020 and subsequently generated tens of billions of dollars in revenue.

However, a lot has changed in the past few years. Although Moderna's COVID-19 vaccines remain its primary revenue stream, sales are just a fraction of what they were during the pandemic. Plus, the company is losing money hand over fist, posting a $2.8 billion net loss in 2025 and expecting billions in losses in 2026 as well.

Details

Based on this, you might think Moderna would be a terrible investment. But I'm not sure that's the case, and there are three main reasons why.

Continue reading

Source

Originally published at www.fool.com.

Related Articles

• Stocks making the biggest moves premarket: GSK, Nuvalent, J.M. Smucker, SailPoint and more
• Stocks are recovering from a sell-off — but even bullish investors warn of a bumpy ride ahead
• Oracle’s stock has surged on AI hype. Now it has to deliver the earnings to match.